RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…

Subcategories:Clinical Criteria/GuidelinesEthicsLegal UpdatesLegislation & AdvocacyMeeting ReportsResearch Rheum
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
From insights into mentoring and statistics to integrating virtual reality into a patient’s rehab—the educational sessions offered during the ACR/ARP Annual Meeting will be practical, yet innovative and inspiring…
Results from a one-year study suggest subcutaneous CT-P13, which is biosimilar to infliximab, is as safe and effective for RA patients as intravenous (IV) CT-P13 and IV infliximab…
John Whitesides |
WASHINGTON (Reuters) – Democratic presidential front-runner Joe Biden and rival Bernie Sanders are waging a public battle this week over universal healthcare, staking out competing turf on an issue that has become the most divisive in the party’s primary campaign. The sniping between the two White House contenders, highlighted on Wednesday when Sanders delivered a…
Step therapy (or fail first) policies introduce significant barriers to access to effective treatments for patients with rheumatic diseases. They also impose significant administrative and cost burdens on providers and practices. The ACR and ARP are advocating state governments, Congress and regulatory agencies limit the impact of these policies on access to care by creating…
On July 1, 2019, the Foundation awarded more than 80 grants to a wide range of rheumatology trainees, professionals and institutions. The recipients will receive funding for essential training and career development, as well as for innovative research projects. Their applications were closely examined by experts in different areas of the field to ensure awards…
Evan Mulvihill, MD, MPH |
A senior rheumatologist with extensive experience in the management of systemic lupus erythematosus is asked to help draft clinical guidelines for the treatment of lupus nephritis. Neither she nor her family members receive grant funding nor does she consult with any pharmaceutical or biotechnology companies. She does have strong clinical opinions based on current evidence…
CHICAGO—When Richard Furie, MD, was first asked to speak about lupus at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7, organizers suggested he discuss low disease activity and classification criteria. But Dr. Furie, a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y., and a veteran investigator…
CHICAGO—The world of rheumatology is beginning to harness the promise of the microbiome, with evidence showing components of the gut may help predict response to medication and may be manipulated to improve how well a treatment works, said Jose Scher, MD, at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7. “We can truly exploit…
Research in type I interferon (IFN) driven mouse models of systemic lupus erythematosus (SLE) suggests the microbiome may play a role in the development of autoimmunity. Additionally, changes in diet may induce protective effects in the gut.1 “Microbes in the gut worsen a lupus model related to the interferon pathway,” says Martin A. Kriegel, MD,…